Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.

[1]  A. Mackensen,et al.  T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct , 2013, Leukemia.

[2]  G. Ehninger,et al.  Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells , 2013, Leukemia.

[3]  Andreas Wolf,et al.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.

[4]  H. Rammensee,et al.  Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia , 2012, Leukemia.

[5]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. A. Lazar,et al.  Modulation of antibody effector function. , 2011, Experimental cell research.

[7]  J. Desjarlais,et al.  Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. , 2010, Blood.

[8]  N. Bartlett,et al.  Anti-CD30 Antibodies for Hodgkin Lymphoma , 2010, Current hematologic malignancy reports.

[9]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[10]  H. Rammensee,et al.  A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells , 2009, Leukemia.

[11]  Holly M Horton,et al.  Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. , 2008, Cancer research.

[12]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[13]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Rammensee,et al.  A recombinant bispecific single‐chain antibody induces targeted, supra‐agonistic CD28‐stimulation and tumor cell killing , 2003, European journal of immunology.

[15]  G. Bastert,et al.  Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma , 2002, International journal of cancer.

[16]  A. Plückthun,et al.  Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.

[17]  W. Fiers,et al.  Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives1 , 2000, The Journal of Immunology.

[18]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[19]  A. Zannettino,et al.  Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. , 1997, Blood.

[20]  L. Massuger,et al.  Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients , 1996, International journal of cancer.

[21]  A. Eggermont,et al.  Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. , 1995, Journal of the National Cancer Institute.

[22]  M. Mack,et al.  A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. de Leij,et al.  Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. , 1994, British journal of cancer.

[24]  K. Hehir,et al.  Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor. , 1991, Journal of immunology.

[25]  W. Wilmanns,et al.  Target cell‐induced T cell activation with bi‐ and trispecific antibody fragments , 1991, European journal of immunology.

[26]  K. Okumura,et al.  Preliminary trial of specific targeting therapy against malignant glioma , 1990, The Lancet.

[27]  G. Jung,et al.  An in-vitro model for tumor immunotherapy with antibody heteroconjugates. , 1988, Immunology today.

[28]  H. Müller-Eberhard,et al.  Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[30]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.